Drugs / lovo-cel
lovo-cel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02140554 | Feb 2015 → Jul 2023 | sickle cell disease | Genetix Biotherapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lovo-cel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02140554 ↗ |
| Known as | LentiGlobin | “lovo-cel (bb1111; LentiGlobin for sickle cell disease [SCD]) gene therapy (GT) comprises autologous transplantation of hematopoietic stem and progenitor cells transduced with...” PMID 36161320 ↗ Oct 2022 |
| Known as | LentiGlobin for sickle cell disease | “lovo-cel (bb1111; LentiGlobin for sickle cell disease [SCD]) gene therapy (GT) comprises autologous transplantation of hematopoietic stem and progenitor cells transduced with...” PMID 36161320 ↗ Oct 2022 |
| Route | Intravenous | “administered by IV infusion” NCT02140554 ↗ |